Trade

with

Acura Pharmaceuticals Inc
(NASDAQ: ACUR)
AdChoices
0.5901
+0.0049
+0.84%
After Hours :
-
-
-

Open

0.5967

Previous Close

0.5852

Volume (Avg)

33.92k (75.51k)

Day's Range

0.5800-0.6000

52Wk Range

0.5700-2.12

Market Cap.

28.59M

Dividend Rate ( Yield )

-

Beta

1.79

Shares Outstanding

48.85M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 123.00k

    • Net Income

    • -13.90M

    • Market Cap.

    • 28.59M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -7,290.26

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.79

    • Forward P/E

    • -2.02

    • Price/Sales

    • 144.93

    • Price/Book Value

    • 2.78

    • Price/Cash flow

    • -2.32

      • EBITDA

      • -13.76M

      • Return on Capital %

      • -65.56

      • Return on Equity %

      • -92.54

      • Return on Assets %

      • -65.56

      • Book Value/Share

      • 0.21

      • Shares Outstanding

      • 48.85M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 1.50

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.29

        • Cashflow Estimate

        • 0.14

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 3,400.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -69.21

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 0.51

            • 64.72

            • Pre-Tax Margin

            • -7,290.26

            • 13.77

            • Net Profit Margin

            • -7,290.26

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.89

              • 0.33

              • Current Ratio

              • 7.87

              • 1.52

              • Quick Ratio

              • 7.33

              • 0.87

              • Interest Coverage

              • -22.23

              • 6.77

              • Leverage Ratio

              • 2.12

              • 1.91

              • Book Value/Share

              • 0.21

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.02

                • 65.36

                • P/E Ratio 5-Year High

                • -31.20

                • 237.47

                • P/E Ratio 5-Year Low

                • -1.95

                • 19.71

                • Price/Sales Ratio

                • 147.06

                • 3.63

                • Price/Book Value

                • 2.80

                • 3.39

                • Price/Cash Flow Ratio

                • -2.32

                • 21.83

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -92.54

                    (-30.20)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -65.56

                    (-26.20)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -54.37

                    (-26.60)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • 0.48

                  • 1.80

                  • Asset Turnover

                  • 0.01

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -14.09M
                  Operating Margin
                  -11,455.28
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -2.32
                  Ownership

                  Institutional Ownership

                  67.38%

                  Top 10 Institutions

                  67.04%

                  Mutual Fund Ownership

                  2.35%

                  Float

                  46.12%

                  5% / Insider Ownership

                  17.52%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Extended Market Index Fund

                  •  

                    408,034

                  • 0.00

                  • 0.84

                  • Vanguard Total Stock Mkt Idx

                  •  

                    290,832

                  • 0.00

                  • 0.60

                  • Vanguard Instl Total Stock Market Index

                  •  

                    205,102

                  • 0.00

                  • 0.42

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    93,798

                  • 0.00

                  • 0.19

                  • iShares Micro-Cap

                  •  

                    43,153

                  • 0.00

                  • 0.07

                  • Vanguard Balanced Index Fund

                  •  

                    37,896

                  • -10.61

                  • 0.08

                  • Schwab Total Stock Market Index Fund®

                  •  

                    20,900

                  • 0.00

                  • 0.04

                  • The Vanguard - Total Stk Mkt Idx Trust. CF

                  •  

                    18,555

                  • 0.00

                  • 0.04

                  • Master Extended Market Index Series

                  •  

                    11,590

                  • 0.00

                  • 0.02

                  • USAA Extended Market Index Fund

                  •  

                    11,585

                  • -0.04

                  • 0.02

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Essex Woodlands Health Ventures

                  •  

                    10,284,886

                  • -0.10%

                  • 20.02

                  • Vanguard Group, Inc.

                  •  

                    964,919

                  • +2.70%

                  • 1.98

                  • Geode Capital Management, LLC

                  •  

                    103,847

                  • -0.10%

                  • 0.21

                  • Creative Planning, Inc.

                  •  

                    89,844

                  • -14.76%

                  • 0.18

                  • Financial Advisory Service Inc

                  •  

                    81,983

                  • 0.00%

                  • 0.17

                  • Northern Trust Investments, N.A.

                  •  

                    80,382

                  • -0.35%

                  • 0.16

                  • Mariner Wealth Advisors, LLC

                  •  

                    52,018

                  • 0.00%

                  • 0.11

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Distressed

                  Style

                  Small Value

                  Acura Pharmaceuticals Inc is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary Aversion and Impede Tec...morehnologies. The Company has discovered and developed two proprietary technologies; Aversion Technology and Impede Technology. Its Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Pfizer Inc.s Oxecta or oxycodone HCl tablets CII is the first approved and marketed product utilizing Aversion and is commercialized under its license agreement with a subsidiary of Pfizer, or the Pfizer Agreement. The Company has also developed ...moreits Impede Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. It has 7 additional opioid products utilizing Aversion in various stages of development. It also launched Nexafed commercially in mid-December 2012. The Pfizer Agreement grants Pfizer an exclusive license to develop and commercialize Oxecta. Its potential competitors include, Pain Therapeutics, in collaboration with Pfizer, Purdue Pharma, Atlantic Pharmaceuticals, Egalet Corporation, KemPharm, Shionogi, Nektar Therapeutics, Signature Therapeutics, QRx Pharma, Tris Pharma, Pisgah Labs, and Collegium Pharmaceuticals, Inc. The Company is subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic Act, or the FD&C Act and to a lesser extent, by state and local governments.lessless

                  Key People

                  Robert B. Jones

                  CEO/Director/President

                  Peter A. Clemens

                  CFO/Chief Accounting Officer/Secretary/Senior VP

                  Dr. Albert W. Brzeczko,PhD

                  Vice President, Divisional

                  James F. Emigh

                  Vice President, Divisional

                  Robert A. Seiser

                  Vice President/Treasurer/Controller

                  • Acura Pharmaceuticals Inc

                  • 616 North North Court

                  • Palatine, IL 60067

                  • USA.Map

                  • Phone: +1 847 705-7709

                  • Fax: +1 847 705-5399

                  • acurapharm.com

                  Incorporated

                  2009

                  Employees

                  15

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: